京新药业
(002020)
| 流通市值：85.79亿 | | | 总市值：102.03亿 |
| 流通股本：7.24亿 | | | 总股本：8.61亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,035,689,121.01 | 1,987,184,442.18 | 923,034,058.55 | 4,069,361,419.58 |
| 营业收入 | 3,035,689,121.01 | 1,987,184,442.18 | 923,034,058.55 | 4,069,361,419.58 |
| 二、营业总成本 | 2,402,725,597.87 | 1,550,664,535.52 | 738,160,639.57 | 3,228,447,527.92 |
| 营业成本 | 1,493,224,526.72 | 983,607,384.02 | 451,517,375.92 | 2,028,631,031.74 |
| 税金及附加 | 42,693,929.08 | 30,232,707.26 | 15,761,263.91 | 51,837,379.83 |
| 销售费用 | 451,762,661.66 | 273,257,091.55 | 136,618,685.78 | 600,791,998.77 |
| 管理费用 | 152,788,226.05 | 99,265,875.24 | 49,681,586.57 | 224,361,559.32 |
| 研发费用 | 263,294,831.15 | 164,772,840.2 | 83,028,611.02 | 367,985,203.82 |
| 财务费用 | -1,038,576.79 | -471,362.75 | 1,553,116.37 | -45,159,645.56 |
| 其中:利息费用 | 2,372,665.86 | 1,556,465.32 | 1,165,476.01 | 3,955,681.57 |
| 其中:利息收入 | 38,621,970.73 | 25,703,983.91 | 13,682,364.2 | 61,470,628.73 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -15,333,199.91 | -16,701,364.37 | 941,493.15 | 9,470,848.64 |
| 加:投资收益 | 16,081,863.88 | 12,784,347.93 | 619,367.57 | 17,108,923.46 |
| 资产处置收益 | 6,173,944.38 | 6,123,990.05 | 2,910,918.48 | -574,497.63 |
| 资产减值损失(新) | -50,216,878.57 | -47,359,931.37 | -7,952,749.42 | -47,434,288.51 |
| 信用减值损失(新) | 4,678,548.45 | 2,026,873.98 | 2,340,651.34 | -5,861,197.93 |
| 其他收益 | 41,563,276.07 | 27,145,940.72 | 10,398,433.34 | 49,031,262.71 |
| 四、营业利润 | 635,911,077.44 | 420,539,763.6 | 194,131,533.44 | 862,654,942.4 |
| 加:营业外收入 | 2,560,830.4 | 1,650,455.61 | 519,459.94 | 3,519,542.19 |
| 减:营业外支出 | 13,217,203.22 | 9,658,572.35 | 3,276,626.96 | 1,848,882.54 |
| 五、利润总额 | 625,254,704.62 | 412,531,646.86 | 191,374,366.42 | 864,325,602.05 |
| 减:所得税费用 | 92,550,156.24 | 56,581,212.01 | 25,224,130.91 | 97,657,634.13 |
| 六、净利润 | 532,704,548.38 | 355,950,434.85 | 166,150,235.51 | 766,667,967.92 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 532,704,548.38 | 355,950,434.85 | 166,150,235.51 | 766,667,967.92 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 527,116,107.89 | 351,622,638.41 | 165,203,257.86 | 757,979,439.23 |
| 少数股东损益 | 5,588,440.49 | 4,327,796.44 | 946,977.65 | 8,688,528.69 |
| 扣除非经常损益后的净利润 | 503,341,995.64 | 341,893,824.62 | 155,485,411.11 | 712,080,553.12 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.65 | 0.43 | 0.2 | 0.92 |
| (二)稀释每股收益 | 0.65 | 0.43 | 0.2 | 0.92 |
| 八、其他综合收益 | -360,585.14 | 282,436.32 | 209,371.89 | -91,596.05 |
| 归属于母公司股东的其他综合收益 | -360,585.14 | 282,436.32 | 209,371.89 | -90,221.25 |
| 九、综合收益总额 | 532,343,963.24 | 356,232,871.17 | 166,359,607.4 | 766,576,371.87 |
| 归属于母公司股东的综合收益总额 | 526,755,522.75 | 351,905,074.73 | 165,412,629.75 | 757,889,217.98 |
| 归属于少数股东的综合收益总额 | 5,588,440.49 | 4,327,796.44 | 946,977.65 | 8,687,153.89 |
| 公告日期 | 2026-10-29 | 2026-08-27 | 2026-04-24 | 2026-04-24 |
| 审计意见(境内) | | | | 标准无保留意见 |